Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
Amid so little good news, early clinical trial results for the anti-viral drug remdesivir have offered hope. The drug appeared to help patients recover faster, from 15 days to 11 days. But the newest obstacle may be the uncertainty that surrounds how the drug will be distributed to patients.
A product containing healthy vaginal bacteria has proved effective against recurrent bacterial vaginosis (BV), an extremely common vaginal infection that is associated with preterm birth, HIV infection and problems with in vitro fertilization.
The testing was conducted by Unidos En Salud, a unique partnership between Mission community organizers in the Latino Task Force for COVID-19, UCSF researchers, the City and County of San Francisco, and the San Francisco Department of Public Health.
UCSF is launching a workforce training and technical assistance program in partnership with the California Department of Public Health to facilitate the training of thousands of individuals across the state in public health techniques and strategies, including contact tracing, case investigation and administration, to limit the ongoing spread of COVID-19.